ArriVent BioPharma - AVBP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.67
  • Forecasted Upside: 80.39%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$17.00
▲ +0.11 (0.65%)

This chart shows the closing price for AVBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ArriVent BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVBP

Analyst Price Target is $30.67
▲ +80.39% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ArriVent BioPharma in the last 3 months. The average price target is $30.67, with a high forecast of $35.00 and a low forecast of $27.00. The average price target represents a 80.39% upside from the last price of $17.00.

This chart shows the closing price for AVBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in ArriVent BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2024Jefferies Financial GroupInitiated CoverageBuy$35.00Low
2/20/2024The Goldman Sachs GroupInitiated CoverageBuy$27.00Low
2/20/2024CitigroupInitiated CoverageBuy$30.00Low
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
ArriVent BioPharma logo
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Read More

Today's Range

Now: $17.00
Low: $16.55
High: $17.35

50 Day Range

MA: $19.48
Low: $16.89
High: $22.75

52 Week Range

Now: $17.00
Low: $16.55
High: $25.95

Volume

311,965 shs

Average Volume

202,290 shs

Market Capitalization

$569.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ArriVent BioPharma?

The following Wall Street sell-side analysts have issued stock ratings on ArriVent BioPharma in the last year: Citigroup Inc., Jefferies Financial Group Inc., and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AVBP.

What is the current price target for ArriVent BioPharma?

3 Wall Street analysts have set twelve-month price targets for ArriVent BioPharma in the last year. Their average twelve-month price target is $30.67, suggesting a possible upside of 80.4%. Jefferies Financial Group Inc. has the highest price target set, predicting AVBP will reach $35.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $27.00 for ArriVent BioPharma in the next year.
View the latest price targets for AVBP.

What is the current consensus analyst rating for ArriVent BioPharma?

ArriVent BioPharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVBP will outperform the market and that investors should add to their positions of ArriVent BioPharma.
View the latest ratings for AVBP.

What other companies compete with ArriVent BioPharma?

How do I contact ArriVent BioPharma's investor relations team?

ArriVent BioPharma's physical mailing address is 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073, United States. The company's listed phone number is 628-277-4836 and its investor relations email address is [email protected]. The official website for ArriVent BioPharma is www.arrivent.com. Learn More about contacing ArriVent BioPharma investor relations.